Keeping pace with the elusive Bordetella pertussis

Journal of Infection

Volumn 44, Issue 1, 2002, Pages 7-12

  Grant, C C ^a   Cherry, J D ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS VACCINE;

ANAPHYLAXIS; ANTIBODY RESPONSE; BORDETELLA PERTUSSIS; CHILD HEALTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ERADICATION THERAPY; FEVER; HUMAN; IMMUNITY; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; INJECTION SITE; MORBIDITY; MORTALITY; NONHUMAN; PERTUSSIS; REVIEW; SEIZURE; SIDE EFFECT;

EID: 0036265125     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2001.0932     Document Type: Article

References (78)

1. Deaths from whooping cough
2. Whooping cough and its epidemiological anomalies
3. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: A comparative study
4. An evaluation of pertussis vaccine
5. Pertussis in developing countries: Definition of the problem and prospects for control
6. Pertussis - England and Wales
7. Pertussis epidemic continues
8. Pertussis deaths: Report of 23 cases in the United States, 1992 and 1993
9. Infant pertussis deaths in New South Wales 1996-1997
10. Pertussis hospitalizations and mortality in the United States, 1985-1988. Evaluation of the completeness of national reporting
11. Underreporting of pertussis deaths in the United States: Need for improved surveillance
12. Bordetella pertussis surveillance in England and Wales: 1995-7
13. Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention
14. Pertussis consensus conference
15. Reemergence of pertussis in the highly vaccinated population of the Netherlands: Observations on surveillance data
16. Seasonal influences on pertussis
17. Incidence of pertussis in Canada
18. Relation between vaccination and notification rates for whooping cough in England and Wales
19. Report of the task force on pertussis and pertussis immunization - 1988
20. Epidemiology of pertussis in Hungary
21. The epidemiological situation of pertussis in the Federal Republic of Germany
22. Effectiveness of a whole cell pertussis vaccine in child-care centers and schools
23. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland
24. The epidemiology of pertussis in England and Wales
25. The effect of an accelerated immunization schedule on pertussis in England and Wales
26. Pertussis in Sweden after the cessation of general immunization in 1979
27. Acellular and whole-cell pertussis vaccines in Japan. Report of a visit by US scientists
28. Developments in pertussis immunization in Japan
29. Immunization against pertussis during the first 4 months of life
30. Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth
31. Pertussis immunization in pediatric practice and in public health
32. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany
33. Response of preterm infants to diphtheria-tetanus-pertussis immunizations
34. Pertussis is increasing in unimmunised infants: Is a change in policy needed?
35. The recurrence of whooping cough: Possible implications for assessment of vaccine efficacy
36. Epidemiological determinants of pertussis
37. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine
38. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group
39. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure
40. A placebo-controlled trial of a pertussis-toxoid vaccine
41. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTa) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine
42. Placebo-controlled trial of two acellular pertussis vaccines in Sweden - Protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines
43. Efficacy of a two-component acellular pertussis vaccine in infants
44. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial
45. Pertussis antibodies, protection, and vaccine efficacy after household exposure
46. Comparative efficacy of acellular pertussis vaccines: An analysis of recent trials
47. The science and fiction of pertussis vaccines
48. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine
49. Epidemiology of a small pertussis outbreak in Kent County, Michigan
50. Duration of effectiveness of pertussis vaccine: Evidence from a 10 year community study
51. Pertussis in the United States, 1979: A look at vaccine efficacy
52. Pertussis - New Zealand 1982/83
53. Reflections on the efficacy of pertussis vaccines
54. Efficacy of whole-cell pertussis vaccine in preschool children in the United States
55. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children
56. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: Value of laboratory tests as predictors of clinical performance
57. Symptoms after accelerated immunization
58. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: Detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying
59. Vaccination of children following a previous hypotonic-hyporesponsive episode
60. Re-vaccination of 421 children with a past history of an adverse vaccine reaction in a special immunization service
61. Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of Medicine
62. Comparison of 13 acellular pertussis vaccines: Adverse reactions
63. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT Vaccine Study Group
64. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine
65. Adult immunization with acellular pertussis vaccine
66. A randomized clinical trial of acellular pertussis vaccines in healthy adults: Dose-response comparisons of 5 vaccines and implications for booster immunization
67. The epidemiology of pertussis
68. Early immunization against pertussis with alum precipitated vaccine
69. Pertussis in adults
70. Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis
71. Epidemiological features of pertussis in the United States, 1980-1989
72. Changing epidemiology of pertussis in the United States: Increasing reported incidence among adolescents and adults, 1990-1996
73. Epidemiological, clinical, and laboratory aspects of pertussis in adults
74. Whooping cough in adults
75. Pertussis in adults: Frequency of transmission after household exposure
76. Widespread silent transmission of pertussis in families: Antibody correlates of infection and symptomatology
77. Comparison of values of antibody to Bordetella pertussis antigens in young German and American men
78. Frequency of unrecognized Bordetella pertussis infections in adults